INFORMATION AND ARTICLES ON PANS/PANDAS
Case Report: PANDAS and persistent Lyme Disease With Neuropsychiatric Symptoms: Treatment, Resolution and Recovery
by Amy Cross, Denis Boubouolis, Craig Shimasaki and Charles Ray Jones
The subject of this case report had a concomitant diagnosis of Lyme borreliosis and PANDAS, both of which are consistent with the neuropsychiatric symptoms she experienced. As evidenced by her recovery and resolution of symptoms, treating both the Lyme infection and streptococcal infection, as well as treating the underlying autoimmune etiology of her neuropsychiatric symptoms resulted in a successful outcome. … The post-treatment resolution of these autoantibodies provided pathophysiological support for addressing both the infection(s) and the underlying immune system dysfunction which resulted in a positive medical outcome for this patient.
Cunningham Panel™ effectively identifies acute illness in Sydenham chorea and PANDAS patients
This newly published article by Dr. Madeleine Cunningham and colleagues examines autoantibody biomarkers for basal ganglia encephalitis (BGE) in a set of patients with Sydenham Chorea (SC) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS). Evidence strongly suggests that both PANDAS and SC are manifestations of basal ganglia encephalitis provoked by cross-reactive anti-neuronal antibodies.
See article below as well as the video of Dr. Cunningham’s additional explanations.
Study demonstrates clinical value of the Cunningham Panel™ and accuracy in patients with symptoms of an autoimmune encephalopathy
Cunningham Panel biomarkers and their significance
This newly published study examined whether changes in patient pre- and post-treatment symptoms correlated with changes in anti-neuronal autoantibody titers and the neuronal cell stimulation assay in the Cunningham Panel in patients with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS).
COVID-19 viral infection may increase risk of neuropsychiatric sequelae
Acute neuropsychiatric symptoms in COVID-19 cases are emerging. This newly published article describes the potential impact of COVID-19 viral infections and the risk of developing neuropsychiatric complications.